RNS19 Jul 2024 10:38
Polarean Imaging plc
("Polarean" or the "Company")
Xenon MRI System trade-in agreement entered with the University of Virginia Health Hospital
Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, announces that it has entered into a trade-in agreement to exchange the University of Virginia Health System's ("UVA Health") existing two research hyperpolarisers for two new clinical-grade hyperpolariser systems to be provided by Polarean.
UVA Health is an integrated health system with a world-class academic medical center that includes a Level 1 Trauma Centre, an NCI-designated Comprehensive Cancer Center, and UVA Health Children's, the number one pediatric hospital in Virginia. UVA Health's Hyperpolarized Gas MR Imaging Center faculty pioneered the application of Xenon MRI for a variety of lung diseases, including asthma, cystic fibrosis, and bronchopulmonary dysplasia.
Replacing these research hyperpolarisers is the first step to UVA Health advancing its leadership position in the Mid-Atlantic as a centre of excellence for NIH grants, industry-sponsored trials, and clinical patient referrals for this novel imaging modality. Polarean expects to install the new systems later this year and will collaborate closely with UVA Health to ensure a successful implementation that enhances the Xenon MRI research program and establishes the foundation for clinical Xenon MRI capabilities.
Christopher von Jako, Ph.D, CEO of Polarean, said: "We are delighted to see UVA Health upgrade both of their hyperpolariser systems to clinical grade. This milestone underscores the increasing adoption of Polarean's technology and the continued progress in our strategy to convert previously research-only centres to clinical-grade, in addition to establishing de novo sites. We look forward to working with the team at UVA Health to ensure that their implementation of our Xenon MRI technology is successful as it continues to advance research and move into clinical use."